I read with interest the European-Middle East Orgalutran trial (The European Orgalutran Study Group et al., 2000) and I noticed that the study extensively monitored hormonal assays (LH, FSH, oestradiol) . It is well known that sufficient stimulation of both theca cells and granulosa cells by LH and FSH is required for adequate oestradiol biosynthesis (Short, 1962; Schoot et al., 1992) and hence endometrial proliferation and receptivity. Recent in-vivo evidence also demonstrates that dominant follicle development and oestradiol production are also dependent on late-follicular phase LH concentrations (Zeleznik et al., 1974; Sullivan et al., 1999) . However, in contrast to gonadotrophin-releasing hormone (GnRH) agonists, the suppression of LH secretion by GnRH antagonists is more pronounced than that of FSH (Hall et al., 1988) . Whether this more pronounced suppression could have an impact on clinical outcome is still a matter of debate. I was wondering if a subgroup analysis was done in the antagonisttreated group (those who got pregnant and those who did not) based on the difference in ratios between basal FSH and LH and their concentrations on day of HCG administration. Our findings concur with those of a recently published study on the role of profound suppression of LH during ovarian stimulation, in which no significant differences were found in ovarian response, IVF/intracytoplasmic sperm injection outcome, implantation and early pregnancy loss between women with low day 7 LH levels applying different threshold values (0.5, 0.7 and Ͻ1.0 IU/l) and normal day 7 LH levels (Balasch et al., 2001) . Hum. Reprod., 16, 1636 -1643 . Mannaerts, B., van Hooren, E. and Boerrigter, P. (2000 
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